public health

HHSA of Mendocino County

# COVID-19 Presentation 

## Board of Supervisors Nov 9, 2021

## Cases per day from Date Tested / Casos Diarios Según la Fecha de Prueba



## Burden of COVID-19 in children 5-11 years of age

- 1.9 million cases
- 8,300 hospitalizations
- 2,316 Multisystem Inflammatory Syndrome in Children (MIS-C) cases
- 94 deaths
- Burden extends beyond case counts; school interrupted, lives disrupted


# Leading Causes of Death in Children 5-11 Years of Age, NCHS, 2019 

|  |  |  |  |
| :---: | :---: | :---: | :---: |
| 66 COVID-19associated deathsin children 5-11$10 / 3 / 20-10 / 2 / 2021$ | Chronic lower respiratory diseases | 107 | 0.4 |
|  | Influenza and pneumonia | 84 | 0.3 |
|  | Intentional self-harm (suicide) | 66 | 0.2 |
|  | Cerebrovascular diseases | 56 | 0.2 |
|  | Septicemia | 48 | 0.2 |

CDC
Total population 5-17 years, 2019: 52,715,248

## Indirect impacts of COVID-19 pandemic on children

- Worsening of mental or emotional health
- Widening of existing education gaps
- Decreased physical activity and increased body mass index (BMI)
- Decreased healthcare utilization
- Decreased routine immunizations
- Increase in Adverse Childhood Experiences (ACEs)
- Loss of caregivers


## Other pediatric vaccine preventable diseases: Hospitalizations per year prior to recommended vaccines

|  | Hepatitis A $^{\mathbf{1}}$ | Varicella $^{\mathbf{2}}$ <br> (Chickenpox) | Influenza $^{\mathbf{3}}$ | COVID-19 |
| :---: | :---: | :---: | :---: | :---: |
| Age | 5-14 years | $<20$ years | 5-17 years | 5-11 years |
| Time period | 2005 | $1988-1995$ | $2003-2007$ | Oct 2020-Oct 2021 |
| Hospitalization <br> Burden <br> (per 100,000 population) | $<\mathbf{1}$ | $\mathbf{4 - 3 1}$ | $\mathbf{3 0 - 8 0}$ | $\mathbf{2 5}$ |

## Other vaccine preventable diseases: Deaths per year prior to recommended vaccines

|  | Hepatitis A $^{\mathbf{1}}$ | Meningococcal <br> (ACWY) $^{\mathbf{2}}$ | Varicella $^{\mathbf{3}}$ | Rubella $^{\mathbf{4}}$ | Rotavirus $^{\mathbf{5}}$ | COVID-19 $^{\text {Age }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $<20$ years | $11-18$ years | $5-9$ years | All ages | $<5$ years | 5-11 years |  |
| Time <br> period | $1990-1995$ | $2000-2004$ | $1990-1994$ | $1966-1968$ | $1985-1991$ | Oct 2020- <br> Oct 2021 |
| Average <br> deaths <br> per year | $\mathbf{3}$ | $\mathbf{8}$ | 16 | 17 | 20 | $\mathbf{6 6}$ |

${ }^{1}$ Vogt TM , Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis2008; 197:1282-8.
${ }^{2}$ National Notifiable Diseases Surveillance System with additional serogroup and outcome data from Enhanced Meningococcal Disease Surveillance for 2015 -2019.
${ }^{3}$ Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality. trends before vaccine licensure in the United States, 1970-1994. J infect Dis. 2000;182(2):383-390. doi:10.1086/315714
${ }^{4}$ Roush SW, Murphy TV; Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA2007; 298:2155-63.
${ }^{5}$ Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 1996 Sep; 174 Suppl 1:S5-11.

## Adverse Events of Special Interest <br> Initial Enrollment Group and Safety Expanded Group

- FDA AESIs:
- No anaphylaxis
- No myocarditis/pericarditis
- No Bell's palsy (or facial paralysis/paresis)
- No appendicitis
- CDC Defined AESIs:
- Potential hypersensitivity (angioedema, and predominantly rash and urticaria)
- Arthritis (infective)
- Vasculitis


## Safety Conclusions for 5 to <12 Year Olds

- Reactogenicity was mostly mild to moderate, and short lived
- Observed mild to moderate local reactions (redness, swelling) captured by ediary were more common and systemic reactions (including fever) less common than those in 16-25 year olds
- The observed AE profile in this study did not suggest any safety concerns for BNT162b2 vaccination in children 5 to <12 years of age


## Cumulative Incidence of COVID-19 After Dose 1: 5 to <12 Years of Age



## Vaccine status among Mendocino County residents, by eligible population and total population, through Nov 1,2021

|  | n | \% of the eligible pop. $(N=75,764)$ | \% of the total pop. ( $\mathrm{N}=86,669$ ) |
| :---: | :---: | :---: | :---: |
| Partially vaccinated | 6,800 | 9.0\% | 7.8\% |
| Fully vaccinated | 54,900* | 72.5\% <br> (74.3\% of CA residents) | 63.3\% |
| Total | 61,700 | 81.4\% <br> (82.6\% of CA residents) | 71.2\% |

By age group

## Booster/Additional Dose

Receipients

## 8,000 residents have received booster doses (as of 11/1)

By race/ethnicity


